Description
Product Overview
BPC & TB Blend combines BPC-157 and TB-500 in a single lyophilised research preparation. This 20mg format contains 10mg of each peptide, providing a total peptide content of 20mg.
The two peptide systems are investigated in different but overlapping areas of cellular biology. BPC-157 is commonly studied in experimental models involving cellular migration, adhesion and signalling, while thymosin-beta-related research is associated with actin-linked cytoskeletal processes and cellular movement.
The higher-total-content 20mg format provides researchers with a larger quantity of the same balanced 1:1 blend for controlled laboratory workflows requiring both peptide components.
Product Specification
Product: BPC & TB Blend
BPC-157 content: 10mg
TB-500 content: 10mg
Total peptide content: 20mg
Blend ratio: 1:1
Form: Lyophilised peptide blend
Minimum purity standard: ≥98%
Batch traceability: Maintained
SKU: PB-BPCTB-20
Quality, Testing & Traceability
Pronoia maintains batch traceability for BPC & TB Blend and retains supporting documentation for the supplied research material.
The peptide material is subject to analytical verification, with batch-specific documentation used to assess identity, purity and consistency in accordance with the applicable testing information.
Because analytical reporting can differ between individual peptide materials and blended preparations, any batch-specific test method or result should be interpreted directly from the corresponding Certificate of Analysis.
Certificate of Analysis (COA) and Safety Data Sheet (SDS) documentation are available to support laboratory records and material assessment.
Research Context
BPC-157 and thymosin-beta-related peptides are investigated in laboratory research examining different aspects of cellular signalling, movement and structural biology.
Research areas associated with the individual peptide systems include:
- Cellular migration and motility mechanisms
- Cell adhesion and signalling pathways
- Actin-associated cytoskeletal organisation
- Endothelial and angiogenic signalling models
- Extracellular-matrix and structural tissue research
- Interactions between complementary peptide signalling pathways
BPC-157 has been investigated in experimental models involving fibroblast migration and cellular adhesion signalling. Research involving thymosin beta-4 has explored actin binding, endothelial-cell migration and related cytoskeletal processes.
The BPC & TB formulation provides both peptide components within one research material for controlled studies where these biological systems are being examined together. Research findings associated with the individual peptides should not be interpreted as evidence of a clinically established effect from the combined blend.
Storage & Handling
BPC & TB Blend is supplied in lyophilised form to support stability during storage and laboratory handling.
The product should be maintained under the temperature-controlled conditions specified by Pronoia and the applicable batch documentation, protected from unnecessary heat, moisture and repeated environmental exposure.
Researchers should follow appropriate laboratory procedures when preparing or handling the material and use validated protocols appropriate to their individual experimental requirements.
Where batch-specific storage instructions are supplied, those instructions should take precedence.
Delivery & Documentation
BPC & TB Blend is supplied through Pronoia’s tracked UK delivery service using its established research-product fulfilment process.
Batch traceability is maintained and Certificate of Analysis (COA) and Safety Data Sheet (SDS) documentation are available to support laboratory records and material assessment.
Current dispatch availability and applicable delivery conditions are displayed directly on the product page and remain subject to Pronoia’s delivery terms.
Research Use Statement
BPC & TB Blend supplied by Pronoia Bio is intended strictly for controlled laboratory research and experimental use.
It is not supplied for human or veterinary use and should not be treated as a medicine or consumer healthcare product.
Purchasers are responsible for ensuring that the material is used appropriately within their research environment and in accordance with applicable requirements.
